ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Comments on Li H et al. "A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma".
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immunotherapy Innovations in the Fight against Osteosarcoma: Emerging Strategies and Promising Progress.Pharmaceutics · 2024Review
- Inhibition of PAD4 enhances radiosensitivity and inhibits aggressive phenotypes of nasopharyngeal carcinoma cells.Cellular & molecular biology letters · 2021Article
- Identification of Prognostic and Predictive Osteosarcoma Biomarkers.Medical sciences (Basel, Switzerland) · 2019Review
- Anti-Metastatic Properties of a Marine Bacterial Exopolysaccharide-Based Derivative Designed to Mimic Glycosaminoglycans.Molecules (Basel, Switzerland) · 2016Article
Corrections and comments
- Comment on
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With great interest, we read the article "A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma" (by Li H et al.). This article suggests that high expression of matrix metalloproteinase 9 (MMP-9) is associated with a poor prognosis for patients with osteosarcoma [1]. The result is encouraging. Nevertheless, some flaws existed in this meta-analysis that we would like to point out.
Indexed as
Identifiers
25416443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.